FDA-APPROVED DRUGS TO TREAT OVERWEIGHT AND OBESITY

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES | 2021年 / 59卷 / 08期
关键词：
D O I：
10.3928/02793695-20210702-79
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [21] Repurposing FDA-approved drugs to treat chemical weapon toxicities: Interactive case studies for trainees
    Aleksunes, Lauren M.
    Gray, Joshua P.
    Meshanni, Jaclynn
    Laskin, Jeffrey D.
    Laskin, Debra L.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [22] Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Peters, Eric J.
    Motsinger-Reif, Alison
    Havener, Tammy M.
    Everitt, Lorraine
    Hardison, Nicholas E.
    Watson, Venita G.
    Wagner, Michael
    Richards, Kristy L.
    Province, Mike A.
    McLeod, Howard L.
    PHARMACOGENOMICS, 2011, 12 (10) : 1407 - 1415
  • [23] Repurposing FDA-approved drugs as potential PARP inhibitors
    Eznarriaga, Maria
    Rahman, Taufiq
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (11) : 2516 - 2516
  • [24] RNA as an off-target for FDA-approved drugs
    Fullenkamp, Christopher R.
    Schneekloth, John S.
    NATURE CHEMISTRY, 2023, 15 (10) : 1329 - 1331
  • [25] Pharmacogenetic Labeling of FDA-Approved Drugs A Regulatory Retrospective
    Drozda, Katarzyna
    Pacanowski, Michael A.
    Grimstein, Christian
    Zineh, Issam
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2018, 3 (04): : 545 - 549
  • [26] An analysis of FDA-approved drugs: natural products and their derivatives
    Patridge, Eric
    Gareiss, Peter
    Kinch, Michael S.
    Hoyer, Denton
    DRUG DISCOVERY TODAY, 2016, 21 (02) : 204 - 207
  • [27] Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs
    Lynch, Holly Fernandez
    Sachs, Rachel E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (24): : 2392 - 2393
  • [28] Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens
    Sisk, Jeanne M.
    Frieman, Matthew B.
    ACS INFECTIOUS DISEASES, 2015, 1 (09): : 401 - 402
  • [29] Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV
    Taki, Elahe
    Soleimani, Faezeh
    Asadi, Arezoo
    Ghahramanpour, Hossein
    Namvar, Ali
    Heidary, Mohsen
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (08) : 1135 - 1147
  • [30] An analysis of FDA-approved drugs for inflammation and autoimmune diseases
    Kinch, Michael S.
    Merkel, Janie
    DRUG DISCOVERY TODAY, 2015, 20 (08) : 920 - 923
12345